Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Dupilumab in Aspirin-Exacerbated Respiratory Disease
2019-004889-18Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dupilumab in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD), sponsored by Medical University of Vienna. Primary endpoint: Tolerance to salicylic acid. Started Mar 2022; status: completed.
02
Drugs
03
Conditions
nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD)
Beyond the preview
Go deeper on 2019-004889-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004889-18.